JRCT ID: jRCT2031240245
Registered date:31/07/2024
Specific Drug Use-Results Survey of COMLEX OTIC SOLUTION 1.5%
Basic Information
| Recruitment status | Recruiting |
|---|---|
| Health condition(s) or Problem(s) studied | Otitis externa, Otitis media |
| Date of first enrollment | 31/07/2024 |
| Target sample size | 1020 |
| Countries of recruitment | |
| Study type | Observational |
| Intervention(s) |
Outcome(s)
| Primary Outcome | MIC range, MIC50, MIC80, MIC90 |
|---|---|
| Secondary Outcome |
Key inclusion & exclusion criteria
| Age minimum | Not applicable |
|---|---|
| Age maximum | Not applicable |
| Gender | Both |
| Include criteria | Clinical isolates from ear and ear discharge specimens from otitis externa and otitis media patients |
| Exclude criteria | N/A |
Related Information
| Primary Sponsor | CEOLIA Pharma.Co.Ltd Pharmacovigilance Office, Quality and Safety Assur |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | |
| Secondary ID(s) |
Contact
| Public contact | |
| Name | Pharmacovigilance Office, Quality and Safety Assur CEOLIA Pharma.Co.Ltd |
| Address | 2F, 2-13-10, Torigoe, Taito-ku, Tokyo Tokyo Japan 111-0054 |
| Telephone | +81-3-5829-5878 |
| 2030_ceo@ceolia.co.jp | |
| Affiliation | CEOLIA Pharma.Co.Ltd |
| Scientific contact | |
| Name | Pharmacovigilance Office, Quality and Safety Assur CEOLIA Pharma.Co.Ltd |
| Address | 2F, 2-13-10, Torigoe, Taito-ku, Tokyo Tokyo Japan 111-0054 |
| Telephone | +81-3-5829-5878 |
| 2030_ceo@ceolia.co.jp | |
| Affiliation | CEOLIA Pharma.Co.Ltd |